Evidence map›Paper›PMID 34065826›Full record

ArticleViruses2021

Herpes Simplex Virus Type 2 Mucin-Like Glycoprotein mgG Promotes Virus Release from the Surface of Infected Cells.

Edward Trybala, Nadia Peerboom, Beata Adamiak, Malgorzata Krzyzowska, Jan-Åke Liljeqvist, Marta Bally, Tomas Bergström

Abstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Microorganisms · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Edward TrybalaDepartment of Infectious Diseases, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, SE-413 46 Göteborg, Sweden.
Nadia PeerboomDepartment of Physics, Chalmers University of Technology, SE-412 96 Göteborg, Sweden.
Beata AdamiakDepartment of Infectious Diseases, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, SE-413 46 Göteborg, Sweden.
Malgorzata KrzyzowskaDepartment of Infectious Diseases, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, SE-413 46 Göteborg, Sweden.ORCID 0000-0002-8409-3974
Jan-Åke LiljeqvistDepartment of Infectious Diseases, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, SE-413 46 Göteborg, Sweden.
Marta BallyDepartment of Clinical Microbiology, Umeå University, SE-901 85 Umeå, Sweden.ORCID 0000-0002-5865-8302
Tomas BergströmDepartment of Infectious Diseases, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, SE-413 46 Göteborg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The contribution of virus components to liberation of herpes simplex virus type 2 (HSV-2) progeny virions from the surface of infected cells is poorly understood. We report that the HSV-2 mutant deficient in the expression of a mucin-like membrane-associated glycoprotein G (mgG) exhibited defect in the release of progeny virions from infected cells manifested by ~2 orders of magnitude decreased amount of infectious virus in a culture medium as compared to native HSV-2. Electron microscopy revealed that the mgG deficient virions were produced in infected cells and present at the cell surface. These virions could be forcibly liberated to a nearly native HSV-2 level by the treatment of cells with glycosaminoglycan (GAG)-mimicking oligosaccharides. Comparative assessment of the interaction of mutant and native virions with surface-immobilized chondroitin sulfate GAG chains revealed that while the mutant virions associated with GAGs ~fourfold more extensively, the lateral mobility of bound virions was much poorer than that of native virions. These data indicate that the mgG of HSV-2 balances the virus interaction with GAG chains, a feature critical to prevent trapping of the progeny virions at the surface of infected cells.

Indexed as

Virus ReleaseCell MembraneCells, CulturedGlycoproteinsHerpes SimplexHerpesvirus 2, HumanHost-Pathogen InteractionsHumansMutationViral Envelope ProteinsVirionGlycoproteinsViral Envelope Proteinsglycoprotein mgGglycosaminoglycansherpes simplex virus type 2mucin-like proteinsingle particle analysisvirus release

Identifiers

PMID34065826
PMCPMC8150390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.